ANTI-TUMOR EFFECTS OF A VIRAL VECTOR ENCODING A TOLL-LIKE RECEPTOR AND A TOLL-LIKE RECEPTOR AGONIST Russian patent published in 2021 - IPC A61K31/7088 A61K39/02 A61P35/00 

FIELD: medicine.

SUBSTANCE: group of inventions relates to a method for preventing or reducing premalignant changes in the patient's prostate, comprising administering to a patient a vector, including first and second nucleic acids, where the first nucleic acid encodes TLR5, and the second nucleic acid encodes a secreted flagellin form. Group of inventions also relates to a method of treating prostate cancer in a patient in need thereof, comprising administering to a patient a cell transduced with a vector, comprising a first and a second nucleic acid, wherein the first nucleic acid encodes TLR5, and the second nucleic acid encodes a secreted form of flagellin; and when prostate cancer is selected from prostatic adenocarcinoma, small cell prostate cancer, squamous cell prostate cancer, prostate sarcoma, transplant cell prostate cancer and (or) benign prostatic hyperplasia (BPH).

EFFECT: group of inventions provides prevention of developing prostate cancer.

22 cl, 4 ex, 19 dwg, 9 tbl